FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo - Pharmaceutical Technology

AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory limbo. AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on AstraZeneca’s oral SERD for breast cancer. AbbVie has secured an approval for its ADC in a ultra-rare blood cancer, while the FDA has delayed its decision on AstraZeneca’s oral SERD, camizestrant, in a form of frontline breast cancer. Credit: Poetra.RH / Shutterstock.com. As core operations at the US Food and Drug Administration (FDA) remain stable despite ongoing shifts in senior leadership ,…

Source: Pharmaceutical Technology